{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:02:34Z","timestamp":1783663354867,"version":"3.55.0"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,13]]},"DOI":"10.7759\/cureus.75647","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T14:47:07Z","timestamp":1734101227000},"source":"Crossref","is-referenced-by-count":4,"title":["Parkinson's Disease: Current Treatment Modalities and Emerging Therapies"],"prefix":"10.7759","author":[{"given":"Shabab","family":"Alotaibi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lujain","family":"Alfayez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Alkhudhair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2013.05.019","article-title":"Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems","volume":"76","author":"Garbayo E","year":"2013","unstructured":"Garbayo E, Ansorena E, Blanco-Prieto MJ. Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems. Maturitas. 2013, 76:272-8. 10.1016\/j.maturitas.2013.05.019","journal-title":"Maturitas"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/ph14080717","article-title":"Current therapies in clinical trials of Parkinson's disease: a 2021 update","volume":"14","author":"Prasad EM","year":"2021","unstructured":"Prasad EM, Hung SY. Current therapies in clinical trials of Parkinson's disease: a 2021 update. Pharmaceuticals (Basel). 2021, 14:717. 10.3390\/ph14080717","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cortex.2008.11.010","article-title":"Parkinson's disease: the syndrome, the pathogenesis and pathophysiology","volume":"45","author":"Bartels AL","year":"2009","unstructured":"Bartels AL, Leenders KL. Parkinson's disease: the syndrome, the pathogenesis and pathophysiology. Cortex. 2009, 45:915-21. 10.1016\/j.cortex.2008.11.010","journal-title":"Cortex"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-018-3585-x","article-title":"Understanding multifactorial architecture of Parkinson's disease: pathophysiology to management","volume":"40","author":"Kaur R","year":"2019","unstructured":"Kaur R, Mehan S, Singh S. Understanding multifactorial architecture of Parkinson's disease: pathophysiology to management. Neurol Sci. 2019, 40:13-23. 10.1007\/s10072-018-3585-x","journal-title":"Neurol Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2019.04.004","article-title":"Garcinol, a multifaceted sword for the treatment of Parkinson's disease","volume":"128","author":"Deb S","year":"2019","unstructured":"Deb S, Phukan BC, Mazumder MK, et al.. Garcinol, a multifaceted sword for the treatment of Parkinson's disease. Neurochem Int. 2019, 128:50-7. 10.1016\/j.neuint.2019.04.004","journal-title":"Neurochem Int"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1502165","article-title":"Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach","volume":"34","author":"Antonini A","year":"2018","unstructured":"Antonini A, Stoessl AJ, Kleinman LS, et al.. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach. Curr Med Res Opin. 2018, 34:2063-73. 10.1080\/03007995.2018.1502165","journal-title":"Curr Med Res Opin"},{"key":"ref7","article-title":"Medical Management of Parkinson\u2019s Disease","volume":"33","author":"Goldenberg MM","year":"2008","unstructured":"Goldenberg MM. Medical Management of Parkinson\u2019s Disease. P T. 2008, 33:590-606.","journal-title":"P T"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-020-00939-x","article-title":"Surgical treatment of Parkinson's disease: devices and lesion approaches","volume":"17","author":"Sharma VD","year":"2020","unstructured":"Sharma VD, Patel M, Miocinovic S. Surgical treatment of Parkinson's disease: devices and lesion approaches. Neurotherapeutics. 2020, 17:1525-38. 10.1007\/s13311-020-00939-x","journal-title":"Neurotherapeutics"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20724","article-title":"Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study","volume":"21","author":"Oertel WH","year":"2006","unstructured":"Oertel WH, Wolters E, Sampaio C, et al.. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. Mov Disord. 2006, 21:343-53. 10.1002\/mds.20724","journal-title":"Mov Disord"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1021\/cn5001759","article-title":"Classics in chemical neuroscience: levodopa","volume":"5","author":"Whitfield AC","year":"2014","unstructured":"Whitfield AC, Moore BT, Daniels RN. Classics in chemical neuroscience: levodopa. ACS Chem Neurosci. 2014, 5:1192-7. 10.1021\/cn5001759","journal-title":"ACS Chem Neurosci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2147\/cia.s6456","article-title":"Levodopa in the treatment of Parkinson's disease: an old drug still going strong","volume":"5","author":"Poewe W","year":"2010","unstructured":"Poewe W, Antonini A, Zijlmans JC, Burkhard PR, Vingerhoets F. Levodopa in the treatment of Parkinson's disease: an old drug still going strong. Clin Interv Aging. 2010, 5:229-38. 10.2147\/cia.s6456","journal-title":"Clin Interv Aging"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2014.00331","article-title":"Spontaneous locomotor activity and L-DOPA-induced dyskinesia are not linked in 6-OHDA parkinsonian rats","volume":"8","author":"Sgroi S","year":"2014","unstructured":"Sgroi S, Kaelin-Lang A, Capper-Loup C. Spontaneous locomotor activity and L-DOPA-induced dyskinesia are not linked in 6-OHDA parkinsonian rats. Front Behav Neurosci. 2014, 8:331. 10.3389\/fnbeh.2014.00331","journal-title":"Front Behav Neurosci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1159\/000215875","article-title":"Levodopa: past, present, and future","volume":"62","author":"Hauser RA","year":"2009","unstructured":"Hauser RA. Levodopa: past, present, and future. Eur Neurol. 2009, 62:1-8. 10.1159\/000215875","journal-title":"Eur Neurol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.13750","article-title":"Current and experimental treatments of Parkinson disease: A guide for neuroscientists","volume":"139 Suppl 1","author":"Oertel W","year":"2016","unstructured":"Oertel W, Schulz JB. Current and experimental treatments of Parkinson disease: A guide for neuroscientists. J Neurochem. 2016, 139 Suppl 1:325-37. 10.1111\/jnc.13750","journal-title":"J Neurochem"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60683-8","article-title":"Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial","volume":"384","author":"Gray R","year":"2014","unstructured":"Gray R, Ives N, Rick C, et al.. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014, 384:1196-205. 10.1016\/S0140-6736(14)60683-8","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000314","article-title":"Single-dose pharmacokinetics and pharmacodynamics of IPX203 in patients with advanced parkinson disease: a comparison with immediate-release carbidopa-levodopa and with extended-release carbidopa-levodopa capsules","volume":"42","author":"Modi NB","year":"2018","unstructured":"Modi NB, Mittur A, Rubens R, Khanna S, Gupta S. Single-dose pharmacokinetics and pharmacodynamics of IPX203 in patients with advanced parkinson disease: a comparison with immediate-release carbidopa-levodopa and with extended-release carbidopa-levodopa capsules. Clin Neuropharmacol. 2018, 42:4-8. 10.1097\/WNF.0000000000000314","journal-title":"Clin Neuropharmacol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.6.1.91","article-title":"Parkinson's disease management strategies","volume":"6","author":"Rajput A","year":"2006","unstructured":"Rajput A, Rajput AH. Parkinson's disease management strategies. Expert Rev Neurother. 2006, 6:91-9. 10.1586\/14737175.6.1.91","journal-title":"Expert Rev Neurother"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033447","article-title":"Levodopa and the progression of Parkinson's disease","volume":"351","author":"Fahn S","year":"2004","unstructured":"Fahn S, Oakes D, Shoulson I, et al.. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004, 351:2498-508. 10.1056\/NEJMoa033447","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23829","article-title":"The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease","volume":"26 Suppl 3","author":"Fox SH","year":"2011","unstructured":"Fox SH, Katzenschlager R, Lim SY, et al.. The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2011, 26 Suppl 3:S2-41. 10.1002\/mds.23829","journal-title":"Mov Disord"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.72.suppl_1.i22","article-title":"Medical management of Parkinson's disease","volume":"72 Suppl 1","author":"Clarke CE","year":"2002","unstructured":"Clarke CE. Medical management of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2002, 72 Suppl 1:I22-7. 10.1136\/jnnp.72.suppl_1.i22","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.68.6.685","article-title":"Dopamine agonists: their role in the treatment of Parkinson's disease","volume":"68","author":"Brooks DJ","year":"2000","unstructured":"Brooks DJ. Dopamine agonists: their role in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000, 68:685-9. 10.1136\/jnnp.68.6.685","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/603631","article-title":"Dopamine agonists and pathologic behaviors","volume":"2012","author":"Kelley BJ","year":"2012","unstructured":"Kelley BJ, Duker AP, Chiu P. Dopamine agonists and pathologic behaviors. Parkinsons Dis. 2012, 2012:603631. 10.1155\/2012\/603631","journal-title":"Parkinsons Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2019.06.001","article-title":"Young-onset Parkinson's disease: Its unique features and their impact on quality of life","volume":"65","author":"Mehanna R","year":"2019","unstructured":"Mehanna R, Jankovic J. Young-onset Parkinson's disease: Its unique features and their impact on quality of life. Parkinsonism Relat Disord. 2019, 65:39-48. 10.1016\/j.parkreldis.2019.06.001","journal-title":"Parkinsonism Relat Disord"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005183422004","article-title":"A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa","volume":"342","author":"Rascol O","year":"2000","unstructured":"Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000, 342:1484-91. 10.1056\/NEJM200005183422004","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.66.1.nct90001","article-title":"Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease","volume":"66","author":"Parkinson Study Group CALM Cohort Investigators","year":"2009","unstructured":"Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol. 2009, 66:563-70. 10.1001\/archneur.66.1.nct90001","journal-title":"Arch Neurol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11060525","article-title":"Continuous subcutaneous apomorphine infusion in Parkinson's disease: a single-center, long-term follow-up study of the causes for discontinuation","volume":"11","author":"Henriksen T","year":"2021","unstructured":"Henriksen T, Staines H. Continuous subcutaneous apomorphine infusion in Parkinson's disease: a single-center, long-term follow-up study of the causes for discontinuation. J Pers Med. 2021, 11:525. 10.3390\/jpm11060525","journal-title":"J Pers Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19010364","article-title":"Systematic review on Parkinson's disease medications, emphasizing on three recently approved drugs to control Parkinson's symptoms","volume":"19","author":"Sivanandy P","year":"2021","unstructured":"Sivanandy P, Leey TC, Xiang TC, Ling TC, Wey Han SA, Semilan SL, Hong PK. Systematic review on Parkinson's disease medications, emphasizing on three recently approved drugs to control Parkinson's symptoms. Int J Environ Res Public Health. 2021, 19:364. 10.3390\/ijerph19010364","journal-title":"Int J Environ Res Public Health"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27340","article-title":"Medical and surgical management of advanced Parkinson's disease","volume":"33","author":"Antonini A","year":"2018","unstructured":"Antonini A, Moro E, Godeiro C, Reichmann H. Medical and surgical management of advanced Parkinson's disease. Mov Disord. 2018, 33:900-8. 10.1002\/mds.27340","journal-title":"Mov Disord"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1017\/s031716710000007x","article-title":"COMT inhibitors in Parkinson's disease","volume":"26 Suppl 2","author":"Rivest J","year":"1999","unstructured":"Rivest J, Barclay CL, Suchowersky O. COMT inhibitors in Parkinson's disease. Can J Neurol Sci. 1999, 26 Suppl 2:S34-8. 10.1017\/s031716710000007x","journal-title":"Can J Neurol Sci"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-171225","article-title":"Are there benefits in adding catechol-o methyltransferase inhibitors in the pharmacotherapy of Parkinson's disease patients? A systematic review","volume":"8","author":"Katsaiti I","year":"2018","unstructured":"Katsaiti I, Nixon J. Are there benefits in adding catechol-o methyltransferase inhibitors in the pharmacotherapy of Parkinson's disease patients? A systematic review. J Parkinsons Dis. 2018, 8:217-31. 10.3233\/JPD-171225","journal-title":"J Parkinsons Dis"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00336-1","article-title":"Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial","volume":"15","author":"Ferreira JJ","year":"2016","unstructured":"Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016, 15:154-65. 10.1016\/S1474-4422(15)00336-1","journal-title":"Lancet Neurol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12081","article-title":"Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects","volume":"76","author":"Rocha JF","year":"2013","unstructured":"Rocha JF, Almeida L, Falc\u00e3o A, et al.. Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol. 2013, 76:763-75. 10.1111\/bcp.12081","journal-title":"Br J Clin Pharmacol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.2174\/1871527316666170124165222","article-title":"Monoamine oxidase B inhibitors in Parkinson's disease","volume":"16","author":"Dezsi L","year":"2017","unstructured":"Dezsi L, Vecsei L. Monoamine oxidase B inhibitors in Parkinson's disease. CNS Neurol Disord Drug Targets. 2017, 16:425-39. 10.2174\/1871527316666170124165222","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/med.21561","article-title":"Monoamine oxidase-B inhibitors as potential neurotherapeutic agents: An overview and update","volume":"39","author":"Tripathi RK","year":"2019","unstructured":"Tripathi RK, Ayyannan SR. Monoamine oxidase-B inhibitors as potential neurotherapeutic agents: An overview and update. Med Res Rev. 2019, 39:1603-706. 10.1002\/med.21561","journal-title":"Med Res Rev"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X14666151120123025","article-title":"Current pharmaceutical treatments and alternative therapies of Parkinson's disease","volume":"14","author":"Dong J","year":"2016","unstructured":"Dong J, Cui Y, Li S, Le W. Current pharmaceutical treatments and alternative therapies of Parkinson's disease. Curr Neuropharmacol. 2016, 14:339-55. 10.2174\/1570159X14666151120123025","journal-title":"Curr Neuropharmacol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003735","article-title":"Anticholinergics for symptomatic management of Parkinson's disease","volume":"2002","author":"Katzenschlager R","year":"2003","unstructured":"Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev. 2003, 2002:CD003735. 10.1002\/14651858.CD003735","journal-title":"Cochrane Database Syst Rev"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1002\/mds.5555","article-title":"Management of Parkinson's disease: an evidence-based review","volume":"17 Suppl 4","author":"Lang AE","year":"2002","unstructured":"Lang AE, Lees A. Management of Parkinson's disease: an evidence-based review. Mov Disord. 2002, 17 Suppl 4:S1-166. 10.1002\/mds.5555","journal-title":"Mov Disord"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aws023","article-title":"Cerebral causes and consequences of parkinsonian resting tremor: a tale of two circuits?","volume":"135","author":"Helmich RC","year":"2012","unstructured":"Helmich RC, Hallett M, Deuschl G, Toni I, Bloem BR. Cerebral causes and consequences of parkinsonian resting tremor: a tale of two circuits?. Brain. 2012, 135:3206-26. 10.1093\/brain\/aws023","journal-title":"Brain"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003361","article-title":"Beta-blocker therapy for tremor in Parkinson's disease","volume":"2003","author":"Crosby NJ","year":"2003","unstructured":"Crosby NJ, Deane KH, Clarke CE. Beta-blocker therapy for tremor in Parkinson's disease. Cochrane Database Syst Rev. 2003, 2003:CD003361. 10.1002\/14651858.CD003361","journal-title":"Cochrane Database Syst Rev"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0105-4","article-title":"Non-dopaminergic treatments for motor control in Parkinson's disease","volume":"73","author":"Fox SH","year":"2013","unstructured":"Fox SH. Non-dopaminergic treatments for motor control in Parkinson's disease. Drugs. 2013, 73:1405-15. 10.1007\/s40265-013-0105-4","journal-title":"Drugs"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00249-0","article-title":"Amantadine in the treatment of Parkinson's disease and other movement disorders","volume":"20","author":"Rascol O","year":"2021","unstructured":"Rascol O, Fabbri M, Poewe W. Amantadine in the treatment of Parkinson's disease and other movement disorders. Lancet Neurol. 2021, 20:1048-56. 10.1016\/S1474-4422(21)00249-0","journal-title":"Lancet Neurol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003467","article-title":"Amantadine for dyskinesia in Parkinson's disease","volume":"2003","author":"Crosby NJ","year":"2003","unstructured":"Crosby NJ, Deane KH, Clarke CE. Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst Rev. 2003, 2003:CD003467. 10.1002\/14651858.CD003467","journal-title":"Cochrane Database Syst Rev"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-018-1869-1","article-title":"Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia","volume":"125","author":"Perez-Lloret S","year":"2018","unstructured":"Perez-Lloret S, Rascol O. Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia. J Neural Transm (Vienna). 2018, 125:1237-50. 10.1007\/s00702-018-1869-1","journal-title":"J Neural Transm (Vienna)"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.2217\/nmt-2019-0011","article-title":"Efficacy and safety of extended-release amantadine in levodopa-induced dyskinesias: a meta-analysis","volume":"9","author":"Pajo AT","year":"2019","unstructured":"Pajo AT, Espiritu AI, Jamora RD. Efficacy and safety of extended-release amantadine in levodopa-induced dyskinesias: a meta-analysis. Neurodegener Dis Manag. 2019, 9:205-15. 10.2217\/nmt-2019-0011","journal-title":"Neurodegener Dis Manag"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1002\/jat.1550","article-title":"DNA damage in brain cells and behavioral deficits in mice after treatment with high doses of amantadine","volume":"30","author":"Kaefer V","year":"2010","unstructured":"Kaefer V, Semedo JG, Silva Kahl VF, et al.. DNA damage in brain cells and behavioral deficits in mice after treatment with high doses of amantadine. J Appl Toxicol. 2010, 30:745-53. 10.1002\/jat.1550","journal-title":"J Appl Toxicol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.066191","article-title":"Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease","volume":"310","author":"Hill MP","year":"2004","unstructured":"Hill MP, Ravenscroft P, Bezard E, et al.. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. J Pharmacol Exp Ther. 2004, 310:386-94. 10.1124\/jpet.104.066191","journal-title":"J Pharmacol Exp Ther"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2003.11.065","article-title":"Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque","volume":"485","author":"Bezard E","year":"2004","unstructured":"Bezard E, Hill MP, Crossman AR, Brotchie JM, Michel A, Grim\u00e9e R, Klitgaard H. Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. Eur J Pharmacol. 2004, 485:159-64. 10.1016\/j.ejphar.2003.11.065","journal-title":"Eur J Pharmacol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10542","article-title":"Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset","volume":"18","author":"Hill MP","year":"2003","unstructured":"Hill MP, Bezard E, McGuire SG, et al.. Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset. Mov Disord. 2003, 18:1301-5. 10.1002\/mds.10542","journal-title":"Mov Disord"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23355","article-title":"Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease","volume":"26","author":"Stathis P","year":"2011","unstructured":"Stathis P, Konitsiotis S, Tagaris G, Peterson D. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease. Mov Disord. 2011, 26:264-70. 10.1002\/mds.23355","journal-title":"Mov Disord"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.2174\/1871527318666190314101314","article-title":"Safety and efficacy of levetiracetam for the management of levodopa-induced dyskinesia in patients with Parkinson's disease: a systematic review","volume":"18","author":"Ebada MA","year":"2019","unstructured":"Ebada MA, Alkanj S, Ebada M, et al.. Safety and efficacy of levetiracetam for the management of levodopa-induced dyskinesia in patients with Parkinson's disease: a systematic review. CNS Neurol Disord Drug Targets. 2019, 18:317-25. 10.2174\/1871527318666190314101314","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-010-0472-x","article-title":"Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial","volume":"117","author":"Wolz M","year":"2010","unstructured":"Wolz M, L\u00f6hle M, Strecker K, et al.. Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial. J Neural Transm (Vienna). 2010, 117:1279-86. 10.1007\/s00702-010-0472-x","journal-title":"J Neural Transm (Vienna)"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23687","article-title":"A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease","volume":"26","author":"Wong KK","year":"2011","unstructured":"Wong KK, Alty JE, Goy AG, Raghav S, Reutens DC, Kempster PA. A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease. Mov Disord. 2011, 26:1552-5. 10.1002\/mds.23687","journal-title":"Mov Disord"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review","volume":"34","author":"Seppi K","year":"2019","unstructured":"Seppi K, Ray Chaudhuri K, Coelho M, et al.. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. Mov Disord. 2019, 34:180-98. 10.1002\/mds.27602","journal-title":"Mov Disord"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041470","article-title":"Rivastigmine for dementia associated with Parkinson's disease","volume":"351","author":"Emre M","year":"2004","unstructured":"Emre M, Aarsland D, Albanese A, et al.. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004, 351:2509-18. 10.1056\/NEJMoa041470","journal-title":"N Engl J Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings J","year":"2014","unstructured":"Cummings J, Isaacson S, Mills R, et al.. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014, 383:533-40. 10.1016\/S0140-6736(13)62106-6","journal-title":"Lancet"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.2174\/092986712803414231","article-title":"The importance of the adenosine A(2A) receptor-dopamine D(2) receptor interaction in drug addiction","volume":"19","author":"Filip M","year":"2012","unstructured":"Filip M, Zaniewska M, Frankowska M, Wydra K, Fuxe K. The importance of the adenosine A(2A) receptor-dopamine D(2) receptor interaction in drug addiction. Curr Med Chem. 2012, 19:317-55. 10.2174\/092986712803414231","journal-title":"Curr Med Chem"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2020.1225","article-title":"An update on medical and surgical treatments of Parkinson's disease","volume":"12","author":"Nemade D","year":"2021","unstructured":"Nemade D, Subramanian T, Shivkumar V. An update on medical and surgical treatments of Parkinson's disease. Aging Dis. 2021, 12:1021-35. 10.14336\/AD.2020.1225","journal-title":"Aging Dis"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9343(96)00381-6","article-title":"Gabapentin for parkinsonism: a double-blind, placebo-controlled, crossover trial","volume":"102","author":"Olson WL","year":"1997","unstructured":"Olson WL, Gruenthal M, Mueller ME, Olson WH. Gabapentin for parkinsonism: a double-blind, placebo-controlled, crossover trial. Am J Med. 1997, 102:60-6. 10.1016\/s0002-9343(96)00381-6","journal-title":"Am J Med"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200405000-00007","article-title":"Effects of gabapentin on the motor response to levodopa: a double-blind, placebo-controlled, crossover study in patients with complicated Parkinson disease","volume":"27","author":"Van Blercom N","year":"2004","unstructured":"Van Blercom N, Lasa A, Verger K, Masram\u00f3n X, Sastre VM, Linazasoro G. Effects of gabapentin on the motor response to levodopa: a double-blind, placebo-controlled, crossover study in patients with complicated Parkinson disease. Clin Neuropharmacol. 2004, 27:124-8. 10.1097\/00002826-200405000-00007","journal-title":"Clin Neuropharmacol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1111\/papr.12516","article-title":"Effects of pregabalin in patients with neuropathic pain previously treated with gabapentin: a pooled analysis of parallel-group, randomized, placebo-controlled clinical trials","volume":"17","author":"Markman JD","year":"2017","unstructured":"Markman JD, Jensen TS, Semel D, Li C, Parsons B, Behar R, Sadosky AB. Effects of pregabalin in patients with neuropathic pain previously treated with gabapentin: a pooled analysis of parallel-group, randomized, placebo-controlled clinical trials. Pain Pract. 2017, 17:718-28. 10.1111\/papr.12516","journal-title":"Pain Pract"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S102696","article-title":"Improvement in pain severity category in clinical trials of pregabalin","volume":"9","author":"Parsons B","year":"2016","unstructured":"Parsons B, Argoff CE, Clair A, Emir B. Improvement in pain severity category in clinical trials of pregabalin. J Pain Res. 2016, 9:779-85. 10.2147\/JPR.S102696","journal-title":"J Pain Res"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27344","article-title":"Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies","volume":"33","author":"Palma JA","year":"2018","unstructured":"Palma JA, Kaufmann H. Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies. Mov Disord. 2018, 33:372-90. 10.1002\/mds.27344","journal-title":"Mov Disord"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1036","article-title":"The factors associated with impulse control behaviors in Parkinson's disease: A 2-year longitudinal retrospective cohort study","volume":"8","author":"Kon T","year":"2018","unstructured":"Kon T, Ueno T, Haga R, Tomiyama M. The factors associated with impulse control behaviors in Parkinson's disease: A 2-year longitudinal retrospective cohort study. Brain Behav. 2018, 8:e01036. 10.1002\/brb3.1036","journal-title":"Brain Behav"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25418","article-title":"Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease","volume":"28","author":"Mizuno Y","year":"2013","unstructured":"Mizuno Y, Kondo T. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease. Mov Disord. 2013, 28:1138-41. 10.1002\/mds.25418","journal-title":"Mov Disord"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1524876","article-title":"Istradefylline for the treatment of Parkinson's disease: is it a promising strategy?","volume":"19","author":"Torti M","year":"2018","unstructured":"Torti M, Vacca L, Stocchi F. Istradefylline for the treatment of Parkinson's disease: is it a promising strategy?. Expert Opin Pharmacother. 2018, 19:1821-8. 10.1080\/14656566.2018.1524876","journal-title":"Expert Opin Pharmacother"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S114147","article-title":"Anticonvulsant effects of isomeric nonimidazole histamine H(3) receptor antagonists","volume":"10","author":"Sadek B","year":"2016","unstructured":"Sadek B, Saad A, Schwed JS, Weizel L, Walter M, Stark H. Anticonvulsant effects of isomeric nonimidazole histamine H(3) receptor antagonists. Drug Des Devel Ther. 2016, 10:3633-51. 10.2147\/DDDT.S114147","journal-title":"Drug Des Devel Ther"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.14.6.729","article-title":"Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease","volume":"14","author":"Jenner P","year":"2005","unstructured":"Jenner P. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease. Expert Opin Investig Drugs. 2005, 14:729-38. 10.1517\/13543784.14.6.729","journal-title":"Expert Opin Investig Drugs"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1124\/pr.55.3.2","article-title":"Molecular mechanisms and therapeutical implications of intramembrane receptor\/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons","volume":"55","author":"Agnati LF","year":"2003","unstructured":"Agnati LF, Ferr\u00e9 S, Lluis C, Franco R, Fuxe K. Molecular mechanisms and therapeutical implications of intramembrane receptor\/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons. Pharmacol Rev. 2003, 55:509-50. 10.1124\/pr.55.3.2","journal-title":"Pharmacol Rev"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20822","article-title":"Compulsive drug use linked to sensitized ventral striatal dopamine transmission","volume":"59","author":"Evans AH","year":"2006","unstructured":"Evans AH, Pavese N, Lawrence AD, et al.. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol. 2006, 59:852-8. 10.1002\/ana.20822","journal-title":"Ann Neurol"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000095205.33940.99","article-title":"Anatomy of adenosine A2A receptors in brain: morphological substrates for integration of striatal function","volume":"61","author":"Rosin DL","year":"2003","unstructured":"Rosin DL, Hettinger BD, Lee A, Linden J. Anatomy of adenosine A2A receptors in brain: morphological substrates for integration of striatal function. Neurology. 2003, 61:S12-8. 10.1212\/01.wnl.0000095205.33940.99","journal-title":"Neurology"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.11138\/FNeur\/2018.33.1.007","article-title":"Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal","volume":"33","author":"Ferrari A","year":"2018","unstructured":"Ferrari A, Manca M, Tugnoli V, Pini LA. Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal. Funct Neurol. 2018, 33:7-18. 10.11138\/FNeur\/2018.33.1.007","journal-title":"Funct Neurol"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10420","article-title":"Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism","volume":"18","author":"Mancini F","year":"2003","unstructured":"Mancini F, Zangaglia R, Cristina S, Sommaruga MG, Martignoni E, Nappi G, Pacchetti C. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord. 2003, 18:685-8. 10.1002\/mds.10420","journal-title":"Mov Disord"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23929","article-title":"Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial","volume":"27","author":"Chinnapongse R","year":"2012","unstructured":"Chinnapongse R, Gullo K, Nemeth P, Zhang Y, Griggs L. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial. Mov Disord. 2012, 27:219-26. 10.1002\/mds.23929","journal-title":"Mov Disord"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870100317","article-title":"\"Off\" painful dystonia in Parkinson's disease treated with botulinum toxin","volume":"10","author":"Pacchetti C","year":"1995","unstructured":"Pacchetti C, Albani G, Martignoni E, Godi L, Alfonsi E, Nappi G. \"Off\" painful dystonia in Parkinson's disease treated with botulinum toxin. Mov Disord. 1995, 10:333-6. 10.1002\/mds.870100317","journal-title":"Mov Disord"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.57.5.659","article-title":"The use of botulinum toxin to treat \"striatal\" toes","volume":"57","author":"Giladi N","year":"1994","unstructured":"Giladi N, Meer J, Honigman S. The use of botulinum toxin to treat \"striatal\" toes. J Neurol Neurosurg Psychiatry. 1994, 57:659. 10.1136\/jnnp.57.5.659","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease","volume":"33","author":"Fox SH","year":"2018","unstructured":"Fox SH, Katzenschlager R, Lim SY, et al.. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2018, 33:1248-66. 10.1002\/mds.27372","journal-title":"Mov Disord"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1992.77.2.0223","article-title":"Symptomatic and functional outcome of stereotactic ventralis lateralis thalamotomy for intention tremor","volume":"77","author":"Goldman MS","year":"1992","unstructured":"Goldman MS, Kelly PJ. Symptomatic and functional outcome of stereotactic ventralis lateralis thalamotomy for intention tremor. J Neurosurg. 1992, 77:223-9. 10.3171\/jns.1992.77.2.0223","journal-title":"J Neurosurg"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1159\/000029723","article-title":"A comparison of surgical approaches for the management of tremor: radiofrequency thalamotomy, gamma knife thalamotomy and thalamic stimulation","volume":"72","author":"Niranjan A","year":"1999","unstructured":"Niranjan A, Jawahar A, Kondziolka D, Lunsford LD. A comparison of surgical approaches for the management of tremor: radiofrequency thalamotomy, gamma knife thalamotomy and thalamic stimulation. Stereotact Funct Neurosurg. 1999, 72:178-84. 10.1159\/000029723","journal-title":"Stereotact Funct Neurosurg"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1227\/NEU.0b013e3182350893","article-title":"Gamma knife thalamotomy for Parkinson disease and essential tremor: a prospective multicenter study","volume":"70","author":"Ohye C","year":"2012","unstructured":"Ohye C, Higuchi Y, Shibazaki T, et al.. Gamma knife thalamotomy for Parkinson disease and essential tremor: a prospective multicenter study. Neurosurgery. 2012, 70:526-35; discussion 535-6. 10.1227\/NEU.0b013e3182350893","journal-title":"Neurosurgery"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002087","article-title":"A prospective single-blind study of Gamma Knife thalamotomy for tremor","volume":"85","author":"Witjas T","year":"2015","unstructured":"Witjas T, Carron R, Krack P, et al.. A prospective single-blind study of Gamma Knife thalamotomy for tremor. Neurology. 2015, 85:1562-8. 10.1212\/WNL.0000000000002087","journal-title":"Neurology"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.3098","article-title":"Safety and efficacy of focused ultrasound thalamotomy for patients with medication-refractory, tremor-dominant Parkinson disease: a randomized clinical trial","volume":"74","author":"Bond AE","year":"2017","unstructured":"Bond AE, Shah BB, Huss DS, et al.. Safety and efficacy of focused ultrasound thalamotomy for patients with medication-refractory, tremor-dominant Parkinson disease: a randomized clinical trial. JAMA Neurol. 2017, 74:1412-8. 10.1001\/jamaneurol.2017.3098","journal-title":"JAMA Neurol"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1600159","article-title":"A randomized trial of focused ultrasound thalamotomy for essential tremor","volume":"375","author":"Elias WJ","year":"2016","unstructured":"Elias WJ, Lipsman N, Ondo WG, et al.. A randomized trial of focused ultrasound thalamotomy for essential tremor. N Engl J Med. 2016, 375:730-9. 10.1056\/NEJMoa1600159","journal-title":"N Engl J Med"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-8-61","article-title":"Gamma knife radiosurgery for movement disorders: a concise review of the literature","volume":"8","author":"Elaimy AL","year":"2010","unstructured":"Elaimy AL, Arthurs BJ, Lamoreaux WT, et al.. Gamma knife radiosurgery for movement disorders: a concise review of the literature. World J Surg Oncol. 2010, 8:61. 10.1186\/1477-7819-8-61","journal-title":"World J Surg Oncol"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30403-9","article-title":"Focused ultrasound subthalamotomy in patients with asymmetric Parkinson's disease: a pilot study","volume":"17","author":"Mart\u00ednez-Fern\u00e1ndez R","year":"2018","unstructured":"Mart\u00ednez-Fern\u00e1ndez R, Rodr\u00edguez-Rojas R, Del \u00c1lamo M, et al.. Focused ultrasound subthalamotomy in patients with asymmetric Parkinson's disease: a pilot study. Lancet Neurol. 2018, 17:54-63. 10.1016\/S1474-4422(17)30403-9","journal-title":"Lancet Neurol"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-016-0336-5","article-title":"Levodopa-carbidopa intestinal gel in patients with Parkinson's disease: a systematic review","volume":"30","author":"Wirdefeldt K","year":"2016","unstructured":"Wirdefeldt K, Odin P, Nyholm D. Levodopa-carbidopa intestinal gel in patients with Parkinson's disease: a systematic review. CNS Drugs. 2016, 30:381-404. 10.1007\/s40263-016-0336-5","journal-title":"CNS Drugs"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-012-9439-1","article-title":"Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients","volume":"15","author":"Nyholm D","year":"2013","unstructured":"Nyholm D, Odin P, Johansson A, Chatamra K, Locke C, Dutta S, Othman AA. Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients. AAPS J. 2013, 15:316-23. 10.1208\/s12248-012-9439-1","journal-title":"AAPS J"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00620","article-title":"Levodopa-carbidopa intestinal gel in Parkinson's disease: a systematic review and meta-analysis","volume":"9","author":"Wang L","year":"2018","unstructured":"Wang L, Li J, Chen J. Levodopa-carbidopa intestinal gel in Parkinson's disease: a systematic review and meta-analysis. Front Neurol. 2018, 9:620. 10.3389\/fneur.2018.00620","journal-title":"Front Neurol"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12526","article-title":"Effect of levodopa-carbidopa intestinal gel on non-motor symptoms in patients with advanced Parkinson's disease","volume":"4","author":"Standaert DG","year":"2017","unstructured":"Standaert DG, Rodriguez RL, Slevin JT, et al.. Effect of levodopa-carbidopa intestinal gel on non-motor symptoms in patients with advanced Parkinson's disease. Mov Disord Clin Pract. 2017, 4:829-37. 10.1002\/mdc3.12526","journal-title":"Mov Disord Clin Pract"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.12.012","article-title":"Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes","volume":"21","author":"Antonini A","year":"2015","unstructured":"Antonini A, Yegin A, Preda C, Bergmann L, Poewe W. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. Parkinsonism Relat Disord. 2015, 21:231-5. 10.1016\/j.parkreldis.2014.12.012","journal-title":"Parkinsonism Relat Disord"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12846","article-title":"Peripheral neuropathy associated with levodopa-carbidopa intestinal infusion: a long-term prospective assessment","volume":"23","author":"Merola A","year":"2016","unstructured":"Merola A, Romagnolo A, Zibetti M, Bernardini A, Cocito D, Lopiano L. Peripheral neuropathy associated with levodopa-carbidopa intestinal infusion: a long-term prospective assessment. Eur J Neurol. 2016, 23:501-9. 10.1111\/ene.12846","journal-title":"Eur J Neurol"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10143","article-title":"Mechanisms of deep brain stimulation","volume":"17 Suppl 3","author":"Dostrovsky JO","year":"2002","unstructured":"Dostrovsky JO, Lozano AM. Mechanisms of deep brain stimulation. Mov Disord. 2002, 17 Suppl 3:S63-8. 10.1002\/mds.10143","journal-title":"Mov Disord"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2010.217489","article-title":"Deep brain stimulation can suppress pathological synchronisation in parkinsonian patients","volume":"82","author":"Eusebio A","year":"2011","unstructured":"Eusebio A, Thevathasan W, Doyle Gaynor L, et al.. Deep brain stimulation can suppress pathological synchronisation in parkinsonian patients. J Neurol Neurosurg Psychiatry. 2011, 82:569-73. 10.1136\/jnnp.2010.217489","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060281","article-title":"A randomized trial of deep-brain stimulation for Parkinson's disease","volume":"355","author":"Deuschl G","year":"2006","unstructured":"Deuschl G, Schade-Brittinger C, Krack P, et al.. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006, 355:896-908. 10.1056\/NEJMoa060281","journal-title":"N Engl J Med"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70308-8","article-title":"Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial","volume":"11","author":"Okun MS","year":"2012","unstructured":"Okun MS, Gallo BV, Mandybur G, et al.. Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol. 2012, 11:140-9. 10.1016\/S1474-4422(11)70308-8","journal-title":"Lancet Neurol"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0145-9","article-title":"Long-term outcomes of deep brain stimulation in Parkinson disease","volume":"15","author":"Limousin P","year":"2019","unstructured":"Limousin P, Foltynie T. Long-term outcomes of deep brain stimulation in Parkinson disease. Nat Rev Neurol. 2019, 15:234-42. 10.1038\/s41582-019-0145-9","journal-title":"Nat Rev Neurol"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2019.03.009","article-title":"Stimulation of the globus pallidus internus in the treatment of Parkinson's disease: Long-term results of a monocentric cohort","volume":"64","author":"Lachenmayer ML","year":"2019","unstructured":"Lachenmayer ML, Bettschen C, Bernasconi C, et al.. Stimulation of the globus pallidus internus in the treatment of Parkinson's disease: Long-term results of a monocentric cohort. Parkinsonism Relat Disord. 2019, 64:118-23. 10.1016\/j.parkreldis.2019.03.009","journal-title":"Parkinsonism Relat Disord"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205158","article-title":"Neurostimulation for Parkinson's disease with early motor complications","volume":"368","author":"Schuepbach WM","year":"2013","unstructured":"Schuepbach WM, Rau J, Knudsen K, et al.. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med. 2013, 368:610-22. 10.1056\/NEJMoa1205158","journal-title":"N Engl J Med"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.4321","article-title":"Globus pallidus interna or subthalamic nucleus deep brain stimulation for Parkinson disease: a review","volume":"75","author":"Ramirez-Zamora A","year":"2018","unstructured":"Ramirez-Zamora A, Ostrem JL. Globus pallidus interna or subthalamic nucleus deep brain stimulation for Parkinson disease: a review. JAMA Neurol. 2018, 75:367-72. 10.1001\/jamaneurol.2017.4321","journal-title":"JAMA Neurol"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70264-8","article-title":"Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial","volume":"12","author":"Odekerken VJ","year":"2013","unstructured":"Odekerken VJ, van Laar T, Staal MJ, et al.. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial. Lancet Neurol. 2013, 12:37-44. 10.1016\/S1474-4422(12)70264-8","journal-title":"Lancet Neurol"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907083","article-title":"Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease","volume":"362","author":"Follett KA","year":"2010","unstructured":"Follett KA, Weaver FM, Stern M, et al.. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med. 2010, 362:2077-91. 10.1056\/NEJMoa0907083","journal-title":"N Engl J Med"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2010.260","article-title":"Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues","volume":"68","author":"Bronstein JM","year":"2011","unstructured":"Bronstein JM, Tagliati M, Alterman RL, et al.. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol. 2011, 68:165. 10.1001\/archneurol.2010.260","journal-title":"Arch Neurol"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21753","article-title":"Deep brain stimulation for Parkinson's disease: prevalence of adverse events and need for standardized reporting","volume":"23","author":"Videnovic A","year":"2008","unstructured":"Videnovic A, Metman LV. Deep brain stimulation for Parkinson's disease: prevalence of adverse events and need for standardized reporting. Mov Disord. 2008, 23:343-9. 10.1002\/mds.21753","journal-title":"Mov Disord"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00934","article-title":"Comparison between levodopa-carbidopa intestinal gel infusion and subthalamic nucleus deep-brain stimulation for advanced Parkinson's disease: a systematic review and meta-analysis","volume":"10","author":"Liu XD","year":"2019","unstructured":"Liu XD, Bao Y, Liu GJ. Comparison between levodopa-carbidopa intestinal gel infusion and subthalamic nucleus deep-brain stimulation for advanced Parkinson's disease: a systematic review and meta-analysis. Front Neurol. 2019, 10:934. 10.3389\/fneur.2019.00934","journal-title":"Front Neurol"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.848","article-title":"l-Dopa\/carbidopa intestinal gel and subthalamic nucleus stimulation: Effects on cognition and behavior","volume":"7","author":"Valldeoriola F","year":"2017","unstructured":"Valldeoriola F, Santacruz P, R\u00edos J, et al.. l-Dopa\/carbidopa intestinal gel and subthalamic nucleus stimulation: Effects on cognition and behavior. Brain Behav. 2017, 7:e00848. 10.1002\/brb3.848","journal-title":"Brain Behav"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.3171\/2021.4.JNS21502","article-title":"Utility of GPI+VIM dual-lead deep brain stimulation for Parkinson's disease patients with significant residual tremor on medication","volume":"136","author":"Azghadi A","year":"2022","unstructured":"Azghadi A, Rajagopal MM, Atkinson KA, Holloway KL. Utility of GPI+VIM dual-lead deep brain stimulation for Parkinson's disease patients with significant residual tremor on medication. J Neurosurg. 2022, 136:1364-70. 10.3171\/2021.4.JNS21502","journal-title":"J Neurosurg"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.13228","article-title":"Combining device-aided therapies in Parkinson's disease: a case series and a literature review","volume":"8","author":"Boura I","year":"2021","unstructured":"Boura I, Haliasos N, Giannopoulou \u0399A, Karabetsos D, Spanaki C. Combining device-aided therapies in Parkinson's disease: a case series and a literature review. Mov Disord Clin Pract. 2021, 8:750-7. 10.1002\/mdc3.13228","journal-title":"Mov Disord Clin Pract"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.850805","article-title":"Assistive methodologies for Parkinson's disease tremor management-a health opinion","volume":"10","author":"Dineshkumar V","year":"2022","unstructured":"Dineshkumar V, Dolly DR, Jagannath DJ, Peter JD. Assistive methodologies for Parkinson's disease tremor management-a health opinion. Front Public Health. 2022, 10:850805. 10.3389\/fpubh.2022.850805","journal-title":"Front Public Health"},{"key":"ref108","article-title":"Performance evaluation of smart glove applied to experimental rig to control human hand tremor for Parkinson disease","author":"Kazi S","year":"2010","unstructured":"Kazi S, Azizan A. Zain, ZM, Mailah M. Performance evaluation of smart glove applied to experimental rig to control human hand tremor for Parkinson disease. ACE'10: Proceedings of the 9th WSEAS International Conference on Applications of Computer Engineering. 2010, 306-15.","journal-title":"ACE'10: Proceedings of the 9th WSEAS International Conference on Applications of Computer Engineering"},{"key":"ref109","article-title":"Analysis and control of hand tremor using IOT","volume":"3","author":"Ragul AS","year":"2017","unstructured":"Ragul AS, Zeeshan M, Prem J, Prasanth S, Packiashree SP. Analysis and control of hand tremor using IOT. International Journal for Modern Trends in Science and Technology. 2017, 3:62-7.","journal-title":"International Journal for Modern Trends in Science and Technology"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2017.11.004","article-title":"Towards remote monitoring of Parkinson's disease tremor using wearable motion capture systems","volume":"384","author":"Delrobaei M","year":"2018","unstructured":"Delrobaei M, Memar S, Pieterman M, Stratton TW, McIsaac K, Jog M. Towards remote monitoring of Parkinson's disease tremor using wearable motion capture systems. J Neurol Sci. 2018, 384:38-45. 10.1016\/j.jns.2017.11.004","journal-title":"J Neurol Sci"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1109\/EMBC.2016.7591063","article-title":"Development of a closed-loop system for tremor suppression in patients with Parkinson's disease","volume":"2016","author":"Xu FL","year":"2016","unstructured":"Xu FL, Hao MZ, Xu SQ, Hu ZX, Xiao Q, Lan N. Development of a closed-loop system for tremor suppression in patients with Parkinson's disease. Annu Int Conf IEEE Eng Med Biol Soc. 2016, 2016:1782-5. 10.1109\/EMBC.2016.7591063","journal-title":"Annu Int Conf IEEE Eng Med Biol Soc"},{"key":"ref112","unstructured":"Turkistani A. Development of an effective portable and flexible glove for hand tremor suppression. Thesis. Western Michigan University. (2017). Accessed. December 7, 2024: https:\/\/scholarworks.wmich.edu\/masters_theses\/908\/."},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1109\/IoT-NC.2013.6694054","article-title":"Quantitative assessment of tremor during deep brain stimulation using a wearable glove system","author":"Dai H","year":"2013","unstructured":"Dai H, D'Angelo CT. Quantitative assessment of tremor during deep brain stimulation using a wearable glove system. 2013 IEEE International Workshop of Internet-of-Things Networking and Control (IoT-NC). New Orleans, LA; 2013. 53-7. 10.1109\/IoT-NC.2013.6694054"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1016\/j.cnp.2019.06.002","article-title":"How to do an electrophysiological study of tremor","volume":"4","author":"Vial F","year":"2019","unstructured":"Vial F, Kassavetis P, Merchant S, Haubenberger D, Hallett M. How to do an electrophysiological study of tremor. Clin Neurophysiol Pract. 2019, 4:134-42. 10.1016\/j.cnp.2019.06.002","journal-title":"Clin Neurophysiol Pract"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.3390\/s18010033","article-title":"Correction: automatic classification of tremor severity in Parkinson's disease using a wearable device","volume":"18","author":"Jeon H","year":"2017","unstructured":"Jeon H, Lee W, Park H, et al..  Correction: automatic classification of tremor severity in Parkinson's disease using a wearable device. Sensors (Basel). 2017, 18:33. 10.3390\/s18010033","journal-title":"Sensors (Basel)"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1109\/TOH.2015.2504971","article-title":"Desktop haptic interface for simulation of hand-tremor","volume":"9","author":"Rosati Papini GP","year":"2016","unstructured":"Rosati Papini GP, Fontana M, Bergamasco M. Desktop haptic interface for simulation of hand-tremor. IEEE Trans Haptics. 2016, 9:33-42. 10.1109\/TOH.2015.2504971","journal-title":"IEEE Trans Haptics"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/206511-parkinsons-disease-current-treatment-modalities-and-emerging-therapies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T14:47:13Z","timestamp":1734101233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/206511-parkinsons-disease-current-treatment-modalities-and-emerging-therapies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,13]]},"references-count":116,"URL":"https:\/\/doi.org\/10.7759\/cureus.75647","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,13]]}}}